| name | Silodosin |
| classification | Alpha-1A adrenergic antagonist |
| pharmacokinetics | | absorption | Well absorbed after oral administration, peak plasma concentration typically achieved within 2-4 hours. | | distribution | Relatively extensively distributed in the body, with high concentrations found in the prostate. | | metabolism | Primarily metabolized in the liver, mainly via CYP3A4. | | excretion | Excreted primarily in the urine, both as unchanged drug and metabolites. |
|
| suggested dosage | | adult male | Typically 8 mg once daily, with or without food, for the treatment of benign prostatic hyperplasia (BPH). Individualized dosing may be necessary based on factors like renal function. Consult with a healthcare professional for appropriate dosage. | | specific notes | Dosage adjustments may be required in patients with moderate to severe renal impairment. |
|
| indications | Benign prostatic hyperplasia (BPH), specifically for the symptomatic relief of lower urinary tract symptoms (LUTS). It improves urine flow and reduces nighttime urination (nocturia). |
| safety in pregnancy | | category | Not established; should not be used during pregnancy unless clearly necessary and the potential benefits outweigh the potential risks. Consult with a healthcare professional. | | notes | Animal studies have not shown a conclusive association with adverse effects in the developing embryo or fetus, however, data from human use is limited. The potential effects on labor or delivery are not fully understood. |
|
| safety in breastfeeding | | status | Unknown. It's recommended to discontinue breastfeeding or avoid the medication, as it may pass into breast milk. | | explanation | Although the extent of silodosin transfer into breast milk is unknown, the potential risk to the nursing infant warrants caution. |
|
| side effects | | 1 | | type | Common (1-10% of patients) | | effects | | 1 | Headache | | 2 | Dizziness | | 3 | Nasal congestion | | 4 | Back pain | | 5 | Fatigue | | 6 | Gastrointestinal discomfort (e.g., nausea, diarrhea, constipation) |
|
| | 2 | | type | Uncommon (0.1-1% of patients) | | effects | | 1 | Orthostatic hypotension | | 2 | Hypotension | | 3 | Priapism (prolonged and painful erection), | | 4 | Ejaculatory dysfunction (e.g., decreased libido, reduced ejaculate volume, ejaculatory delay or absence) |
|
| | 3 | | type | Rare (less than 0.1% of patients) | | effects | | 1 | Vision problems | | 2 | Serious allergic reactions | | 3 | Liver problems | | 4 | Serious skin reactions |
|
| | 4 | | type | Potential serious side effects | | effects | | 1 | Sudden drop in blood pressure, especially when standing up (orthostatic hypotension). | | 2 | Prolonged and painful erection (priapism). | | 3 | Severe allergic reactions (anaphylaxis), including difficulty breathing and swelling of the throat, eyes, or lips. |
|
|
|
| alternatives | |
| contraindications | | 1 | Severe hepatic impairment | | 2 | Known hypersensitivity to silodosin or related drugs | | 3 | Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) | | 4 | Patient with a history of priapism. |
|
| interactions | | 1 | | drug | Strong CYP3A4 inhibitors | | mechanism | Increase silodosin levels, potentially leading to increased side effects. | | recommendation | Caution advised; dosage adjustments may be necessary or alternative medication should be considered. Consult with a healthcare provider. |
| | 2 | | drug | Strong CYP3A4 inducers | | mechanism | Decrease silodosin levels, potentially reducing its effectiveness. | | recommendation | Caution advised; dosage adjustments may be necessary or alternative medication should be considered. Consult with a healthcare provider. |
|
|
| warnings and precautions | | 1 | Monitor blood pressure, particularly during the initial period of treatment or dosage adjustments. | | 2 | Patients with pre-existing cardiovascular conditions should be closely monitored for hypotension. | | 3 | Caution is required in patients with a history of liver or kidney dysfunction. | | 4 | Avoid alcohol consumption, which may exacerbate orthostatic hypotension. |
|
| additional information | | 1 | In patients with severe renal impairment, dosage adjustments may be needed or alternate medications should be considered. | | 2 | Do not discontinue medication abruptly without consulting a healthcare professional. | | 3 | Be aware of the potential for ejaculatory dysfunction. This is usually temporary and may resolve over time. |
|
| patient data | |
